Ranbaxy to shift focus to generics
Ranbaxy Laboratories has said that it is shifting the focus of its research from the development of new drugs to that of generic drugs for effecting better synergy with its Japanese parent, Daiichi Sankyo.
Ranbaxy Pharmaceuticals has halted productions of its generic version of the cholesterol drug Lipitor after recalling a second batch of tablets in the 10mg, 20mg, and 40mg dosage strengths.